

biocrates life sciences ag, global leader in mass spectrometry-based quantitative metabolite profiling, becomes part of Bruker Group

Innsbruck, Austria, June 3, 2025 – Bruker Corporation (NASDAQ: BRKR) today announced the full acquisition of biocrates life sciences ag. biocrates, located in Innsbruck, Austria is the global leader in mass spectrometry-based quantitative metabolite and lipid analysis, offering kits, software, and services that make standardized metabolomics accessible.

biocrates life sciences ag, founded in 2002, has been consistently backed by MIG and ARAX Funds in developing its core technologies that are now used by hundreds of laboratories worldwide. biocrates has grown into a category leader in the science of metabolomics, enabling researchers to measure more than 1,800 biomarkers from a single drop of blood.



“We are incredibly proud of the biocrates team and what they’ve accomplished,” said Dr. Matthias Kromayer, General Partner at MIG. “Through exceptional vision, execution, and resilience, they have built a truly unique technology. We’re grateful to have been part of the journey. This exit underscores MIG’s ongoing long-term commitment to backing visionary entrepreneurs and scaling transformative technologies.”



“MIG and ARAX Funds have been more than just investors – they’ve been true partners,” said Dr. Sebastian Gottfried, CMO of biocrates. “Their support, insight, and belief in our mission were instrumental in getting us to this point. We’re excited about what lies ahead with Bruker, and we thank MIG and ARAX Funds and their respective investors for their role in helping us reach this milestone.”



“Joining Bruker is a major milestone and a strong validation of our team’s hard work and vision”, said Moritz Seuster, CEO of biocrates. “What makes this partnership so powerful is our shared passion for multiomics and biocrates’ continued commitment to supporting and innovating across multiple MS technologies and vendors. With Bruker, we’re poised to scale our impact while staying true to our mission to make omics quantitative, reproducible, and easily accessible. We’re deeply thankful to our employees, customers, and partners who made this possible.”

About biocrates life sciences ag

biocrates life sciences ag is the world leader in quantitative, mass-spectrometry-based metabolomics. Founded in 2002 and headquartered in Innsbruck, Austria, the company delivers standardized kits, software, and contract research services that enable laboratories to quantify up to 1,881 biomarkers in a single kit from less than one drop of blood. Researchers worldwide rely on flagship kits such as MxP® Quant 1000 to transform metabolic data from diverse tissues and sample types into actionable biomarkers, accelerated drug development, and more precise healthcare.

For more information, visit biocrates.com and follow [biocrates on LinkedIn](#).

About MIG Capital

MIG Capital is one of the leading German VC investors. Through its MIG funds, MIG invests in young deep tech and life sciences companies in German-speaking Europe and beyond. To date, the company has invested over €730 million in more than 50 start-ups. MIG portfolio companies develop innovations in areas including biopharmaceuticals, energy and environmental technologies, advanced computing, digitalization / IoT, medical technology, and digital health.

In recent years, MIG Capital has realized more than ten successful portfolio company sales, including Siltectra (to Infineon) and Hemovent (to MicroPort). It has placed several companies on the stock exchange, including BRAIN, NFON, BioNTech, and Immatix. For further information, please visit: mig.ag, mig-fonds.de. LinkedIn [MIG Capital](#)

About ARAX Capital Partners

ARAX Capital Partners specializes in financing promising Austrian technology and life science companies. Our focus is on supporting and developing young companies that are characterized by sound concepts and pioneering technologies, coupled with sustainable value creation potential. ARAX Capital Partners makes a significant contribution to success through strategic support throughout the entire development phase and pursues the goal of supporting the most innovative Austrian companies in realizing their visions.

Media contact

biocrates life sciences ag

Sebastian Gottfried, Ph.D.

Chief Marketing Officer

sebastian.gottfried@biocrates.com